Cargando…
An Update on Development of Small-Molecule Plasmodial Kinase Inhibitors
Malaria control relies heavily on the small number of existing antimalarial drugs. However, recurring antimalarial drug resistance necessitates the continual generation of new antimalarial drugs with novel modes of action. In order to shift the focus from only controlling this disease towards elimin...
Autores principales: | Moolman, Chantalle, van der Sluis, Rencia, Beteck, Richard M., Legoabe, Lesetja J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664427/ https://www.ncbi.nlm.nih.gov/pubmed/33171706 http://dx.doi.org/10.3390/molecules25215182 |
Ejemplares similares
-
Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review
por: Angula, Klaudia T., et al.
Publicado: (2021) -
Quinolone: a versatile therapeutic compound class
por: Dube, Phelelisiwe S., et al.
Publicado: (2022) -
Plasmodial Kinase Inhibitors Targeting Malaria: Recent Developments
por: Mustière, Romain, et al.
Publicado: (2020) -
Plasmodial Kinase Inhibitors: License to Cure?
por: Cabrera, Diego González, et al.
Publicado: (2018) -
Exploration of 4-aminopyrrolo[2,3-d]pyrimidine as antitubercular agents
por: Jesumoroti, Omobolanle Janet, et al.
Publicado: (2022)